Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04229979
Title Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (REGAL)
Acronym REGAL
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Sellas Life Sciences Group
Age Groups: senior | adult
Covered Countries USA | FRA | ESP | DEU

No variant requirements are available.